BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38421735)

  • 1. Small molecules that disrupt RAD54-BLM interaction hamper tumor proliferation in colon cancer chemoresistance models.
    Kaur E; Agrawal R; Arun R; Madhavan V; Srivastava V; Kumar D; Rath PP; Kumar N; Vedagopuram S; Pandey N; Priya S; Legembre P; Gourinath S; Bajaj A; Sengupta S
    J Clin Invest; 2024 Feb; 134(8):. PubMed ID: 38421735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BLM helicase stimulates the ATPase and chromatin-remodeling activities of RAD54.
    Srivastava V; Modi P; Tripathi V; Mudgal R; De S; Sengupta S
    J Cell Sci; 2009 Sep; 122(Pt 17):3093-103. PubMed ID: 19671661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BLM has early and late functions in homologous recombination repair in mouse embryonic stem cells.
    Chu WK; Hanada K; Kanaar R; Hickson ID
    Oncogene; 2010 Aug; 29(33):4705-14. PubMed ID: 20531307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological targeting of RAD6 enzyme-mediated translesion synthesis overcomes resistance to platinum-based drugs.
    Sanders MA; Haynes B; Nangia-Makker P; Polin LA; Shekhar MP
    J Biol Chem; 2017 Jun; 292(25):10347-10363. PubMed ID: 28490629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new herbal formula BP10A exerted an antitumor effect and enhanced anticancer effect of irinotecan and oxaliplatin in the colon cancer PDTX model.
    Kim J; Kim HY; Hong S; Shin S; Kim YA; Kim NS; Bang OS
    Biomed Pharmacother; 2019 Aug; 116():108987. PubMed ID: 31112870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-409-3p sensitizes colon cancer cells to oxaliplatin by inhibiting Beclin-1-mediated autophagy.
    Tan S; Shi H; Ba M; Lin S; Tang H; Zeng X; Zhang X
    Int J Mol Med; 2016 Apr; 37(4):1030-8. PubMed ID: 26935807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Curcumin β-D-glucuronide exhibits anti-tumor effects on oxaliplatin-resistant colon cancer with less toxicity in vivo.
    Ozawa-Umeta H; Kishimoto A; Imaizumi A; Hashimoto T; Asakura T; Kakeya H; Kanai M
    Cancer Sci; 2020 May; 111(5):1785-1793. PubMed ID: 32163218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome-wide single-nucleotide resolution of oxaliplatin-DNA adduct repair in drug-sensitive and -resistant colorectal cancer cell lines.
    Vaughn CM; Selby CP; Yang Y; Hsu DS; Sancar A
    J Biol Chem; 2020 May; 295(22):7584-7594. PubMed ID: 32299912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and evaluation of N3-substituted quinazolinone derivatives as potential Bloom's Syndrome protein (BLM) helicase inhibitor for sensitization treatment of colorectal cancer.
    Tu JL; Wu BH; Wu HB; Wang JE; Zhang ZL; Gao KY; Zhang LX; Chen QR; Zhou YC; Tan JH; Huang ZS; Chen SB
    Eur J Med Chem; 2023 Jan; 246():114944. PubMed ID: 36459756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Embryonic stem cells deficient for Brca2 or Blm exhibit divergent genotoxic profiles that support opposing activities during homologous recombination.
    Marple T; Kim TM; Hasty P
    Mutat Res; 2006 Dec; 602(1-2):110-20. PubMed ID: 16997331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Possible association of BLM in decreasing DNA double strand breaks during DNA replication.
    Wang W; Seki M; Narita Y; Sonoda E; Takeda S; Yamada K; Masuko T; Katada T; Enomoto T
    EMBO J; 2000 Jul; 19(13):3428-35. PubMed ID: 10880455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin revert insulin-induced oxaliplatin resistance by activating mitochondrial apoptosis pathway in human colon cancer HCT116 cells.
    Liu C; Liu Q; Yan A; Chang H; Ding Y; Tao J; Qiao C
    Cancer Med; 2020 Jun; 9(11):3875-3884. PubMed ID: 32248666
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Qu J; Sun Z; Peng C; Li D; Yan W; Xu Z; Hou Y; Shen S; Chen P; Wang T
    Int J Biol Sci; 2021; 17(11):2756-2769. PubMed ID: 34345205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AURKA Increase the Chemosensitivity of Colon Cancer Cells to Oxaliplatin by Inhibiting the TP53-Mediated DNA Damage Response Genes.
    Shan B; Zhao R; Zhou J; Zhang M; Qi X; Wang T; Gong J; Wu Y; Zhu Y; Yang W; Zhang Y; Wang G; Li X
    Biomed Res Int; 2020; 2020():8916729. PubMed ID: 32851091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RKIP phosphorylation and STAT3 activation is inhibited by oxaliplatin and camptothecin and are associated with poor prognosis in stage II colon cancer patients.
    Cross-Knorr S; Lu S; Perez K; Guevara S; Brilliant K; Pisano C; Quesenberry PJ; Resnick MB; Chatterjee D
    BMC Cancer; 2013 Oct; 13():463. PubMed ID: 24098947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemosensitivity of resistant colon cancer cell lines to lobaplatin, heptaplatin, and dicycloplatin.
    Wei W; Liu Z; Chen X; Bi F
    Int J Clin Pharmacol Ther; 2014 Aug; 52(8):702-7. PubMed ID: 24986092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mouse Rad54 affects DNA conformation and DNA-damage-induced Rad51 foci formation.
    Tan TL; Essers J; Citterio E; Swagemakers SM; de Wit J; Benson FE; Hoeijmakers JH; Kanaar R
    Curr Biol; 1999 Mar; 9(6):325-8. PubMed ID: 10209103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential contributions of mammalian Rad54 paralogs to recombination, DNA damage repair, and meiosis.
    Wesoly J; Agarwal S; Sigurdsson S; Bussen W; Van Komen S; Qin J; van Steeg H; van Benthem J; Wassenaar E; Baarends WM; Ghazvini M; Tafel AA; Heath H; Galjart N; Essers J; Grootegoed JA; Arnheim N; Bezzubova O; Buerstedde JM; Sung P; Kanaar R
    Mol Cell Biol; 2006 Feb; 26(3):976-89. PubMed ID: 16428451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polarity and bypass of DNA heterology during branch migration of Holliday junctions by human RAD54, BLM, and RECQ1 proteins.
    Mazina OM; Rossi MJ; Deakyne JS; Huang F; Mazin AV
    J Biol Chem; 2012 Apr; 287(15):11820-32. PubMed ID: 22356911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kaempferol sensitizes cell proliferation inhibition in oxaliplatin-resistant colon cancer cells.
    Park J; Lee GE; An HJ; Lee CJ; Cho ES; Kang HC; Lee JY; Lee HS; Choi JS; Kim DJ; Choi JS; Cho YY
    Arch Pharm Res; 2021 Dec; 44(12):1091-1108. PubMed ID: 34750753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.